Efficacy, safety, and tolerability of oral Cebranopadol versus morphine sulphate PR in subjects with chronic moderate to severe pain related to cancer
Latest Information Update: 16 Jul 2021
At a glance
- Drugs Cebranopadol (Primary) ; Morphine
- Indications Cancer pain
- Focus Registrational; Therapeutic Use
- Acronyms CORAL
- Sponsors Tris Pharma
- 30 Sep 2016 Interim results (n=126) presented at the 16th World Congress on Pain
- 30 Sep 2016 According to Grunenthal's Media Release, study was stopped because of strategic reasons and results from this study will be presented at the IASP conference in 2016.
- 30 Sep 2016 According to Grunenthal's Media Release, Primary endpoint has been met. (Average amount of daily rescue medication at the end of the maintenance period.)